NCT00984815已完成3 期
Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 86
- 试验地点
- 4
- 主要终点
- Number of Participants With Treatment Emergent Adverse Events
研究概览
简要总结
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
详细描述
HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor antagonist (H2RA), is being developed for the treatment of patients with signs and symptoms of osteoarthritis, rheumatoid arthritis, mild to moderate pain or dysmenorrhea who are at risk of developing ibuprofen-associated upper gastrointestinal ulcers.
Study with completed results acquired from Horizon in 2024.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.
- •Patient is male or female, aged 40 to 80 years of age.
- •Patient is expected to require daily administration of an NSAID for at least the coming year for conditions including but not limited to: osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, chronic soft tissue pain.
- •Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the entire study period.
- •Patient is willing and able to comply with the prescribed treatment protocol and evaluations.
排除标准
- •Patient has a history of or experienced any of the following:
- •NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding
- •NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis
- •Malignant disease of the gastrointestinal tract
- •Erosive esophagitis
- •Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0
- •Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c > 7%
- •Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
- •Patient has active cardiac, renal, and/or hepatic disease, as evidenced by:
- •Creatinine clearance < 45 mL/min (based on the Cockroft-Gault formula) at Screening
- •Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at Screening
- •History of acute myocardial infarction, unstable cardiac arrhythmias, and/or stroke within the 6 months prior to study entry
- •Uncontrolled congestive heart failure
- •Uncontrolled hypertension
- •Patient currently is participating in an investigational drug study, or patient participated in an investigational drug study within the 30 days prior to study entry.
- •Female patient has a positive urine pregnancy test at Screening and/or Study Day
- •Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk.
研究组 & 干预措施
HZT-501
Experimental
Open-label treatment with HZT-501
干预措施: HZT-501 (Drug)
结局指标
主要结局
Number of Participants With Treatment Emergent Adverse Events
时间窗: 54 weeks
次要结局
- Change From Baseline in the Pain Intensity Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks(Baseline and 54 Weeks)
- Change From Baseline in the Non-pain Symptoms Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks(Baseline and 54 Weeks)
- Change From Baseline in the Satisfaction With Dyspepsia-Related Health Scale of the Severity of Dyspepsia Assessment (SODA) Questionnaire at 54 Weeks(Baseline and 54 Weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)Chronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue PainRheumatoid ArthritisOsteoarthritisNCT00613106Amgen179
已完成
3 期
Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated UlcersPeptic UlcerNCT00450658Amgen627
已完成
3 期
Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) TreatmentUlcerNCT00450216Amgen906
终止
2 期
Study of HST5040 in Subjects With Propionic or Methylmalonic AcidemiaPropionic AcidemiaMethylmalonic AcidemiaNCT04732429HemoShear Therapeutics26
已完成
3 期
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity DisorderNCT00969618Eli Lilly and Company211